Diligence memo · auto-generated · as of July 2, 2026
rMark Bio, Inc.
rMark Bio, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
rMark Bio, Inc. operates in Biotech / Pharma, based in Chicago.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
rMark Bio, Inc. has raised $4.5M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.8M on 2019-10-03.
Most recent recorded round closed around 2019-10-03.
Valuation (modeled)modeled
Provath models rMark Bio, Inc. at approximately $114M (range $2.0M–$895M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.36× the median modeled value of Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 6.7 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 47% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: Massive Bio, Inc., Light Bio, Inc., Agronomed Pharmaceuticals LLC, Cellix Biosciences, Inc., xD Bio, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.